Nanoscope Therapeutics has moved one of the most unusual retinal gene-therapy programs into formal U.S. regulatory review after the Food and Drug Administration accepted and filed the Biologics License Application for MOGENRY, or sonpiretigene isteparvovec, formerly known as MCO-010. The intravitreal optogenetic therapy is being developed for people with retinitis pigmentosa who have severe vision loss, and the company says the FDA has assigned a Prescription Drug User Fee Act target date in the first half of 2027. If approved, MOGENRY would be positioned as the first gene-agnostic treatment for this patient population, meaning eligibility would not depend on which of the many different genetic mutations caused the retinal degeneration.
That distinction is potentially important because retinitis pigmentosa is not one genetic disease. It is a broad group of inherited retinal disorders caused by mutations across many genes, and patients can progressively lose night vision, peripheral vision and eventually central visual function as photoreceptors degenerate. Existing gene-replacement strategies are generally mutation specific because they attempt to supply or correct the gene responsible for disease. MOGENRY takes a very different route: instead of repairing the original photoreceptor mutation, it attempts to make surviving inner retinal cells responsive to light after the photoreceptors themselves have largely failed.
How can MOGENRY restore light sensitivity without repairing the original disease-causing gene?
The biological idea behind optogenetics is to introduce a light-sensitive protein into retinal cells that ordinarily would not perform the photoreceptor’s job. In advanced retinitis pigmentosa, rods and cones may be severely damaged or lost, but substantial portions of the downstream retinal circuitry can remain anatomically present. Nanoscope’s strategy is designed to exploit those surviving cells rather than depending on damaged photoreceptors being rescued.
MOGENRY uses an adeno-associated viral vector to deliver a multi-characteristic opsin, or MCO, gene into inner retinal cells. The company’s premise is that once those cells express the engineered opsin, they can respond directly to ambient light and pass visual information through the remaining retinal network toward the brain. This is fundamentally different from conventional gene replacement because the therapy does not need to know whether the patient has a mutation in one particular RP gene before treatment.
The gene-agnostic approach could broaden the addressable patient population substantially if it works reliably. A mutation-specific therapy may only be suitable for a small genetic subgroup even when the broader disease name is common enough to be recognizable. MOGENRY instead targets the functional consequence of many different mutations: advanced photoreceptor loss.
That advantage comes with a major scientific trade-off. The therapy is not restoring normal rods and cones or reconstructing the retina to its original state. It is attempting to reroute light sensing through cells that were not naturally designed to serve as primary photoreceptors, which means the quality, resolution, contrast and adaptability of restored vision may differ from normal vision.
What evidence is supporting the FDA application?
Nanoscope says the BLA is supported by the Phase 1/2a program, the randomized Phase 2b/3 RESTORE study and longer-term follow-up through REMAIN. RESTORE was designed as a multicenter, randomized, double-masked, sham-controlled trial, giving the efficacy evidence a substantially stronger foundation than an uncontrolled proof-of-concept study. The company says RESTORE met its primary and key secondary endpoints and showed improvements in visual acuity at weeks 52 and 76.
The sham-controlled design is particularly important in severe visual impairment because functional vision testing can be influenced by learning, expectation and repeated exposure to the assessment. Randomizing patients to an injection procedure that does not contain active therapy helps separate the treatment effect from those influences. The long duration is also relevant because an AAV-delivered therapy is intended to produce sustained protein expression rather than a short-lived pharmacological effect.
However, the current FDA-acceptance announcement does not reproduce the full RESTORE numerical dataset. Readers should therefore not interpret acceptance of the BLA as an FDA conclusion that the magnitude of visual improvement is already proven clinically meaningful. Acceptance primarily means the agency has determined the application is sufficiently complete to undergo substantive review.
The key regulatory debate will involve how much vision was regained, how consistently the improvement occurred across patients, how durable it remained and whether functional gains were large enough to matter in ordinary daily life. Those questions will determine whether the biological ingenuity of the optogenetic approach translates into a therapy patients actually value.
Why is severe retinitis pigmentosa such a difficult stage to treat?
Many retinal therapies are easiest to conceptualize early in disease, when photoreceptors remain alive and can potentially be preserved. Severe RP presents the opposite problem. By the time patients have profound vision loss, much of the original light-sensing tissue may already be gone, making ordinary rescue strategies much less plausible.
That is why MOGENRY is being developed specifically around advanced loss. Rather than trying to save photoreceptors that may no longer exist in sufficient numbers, the therapy attempts to repurpose the cells that remain downstream.
The strategy could fill a significant treatment gap if approved because patients with severe RP frequently have very limited therapeutic options beyond supportive low-vision services. Mutation-specific genetic therapies are relevant only to selected subgroups, while many patients with advanced disease do not have an approved intervention capable of restoring useful vision.
The regulatory bar is nevertheless demanding because “some vision improvement” does not automatically equal meaningful benefit. The FDA will need to judge whether the magnitude of improvement translates into better mobility, reading, object recognition or other functional outcomes sufficiently important to justify the risks of an irreversible gene therapy.
Why is an intravitreal injection potentially easier than subretinal gene therapy?
MOGENRY is delivered through an intravitreal injection into the vitreous cavity of the eye. That route is already familiar to ophthalmologists because millions of intravitreal injections are performed for retinal diseases using anti-VEGF and other medicines.
Some retinal gene therapies instead require subretinal delivery, in which a surgeon places the vector underneath the retina during a much more complex vitreoretinal procedure. Subretinal administration can target photoreceptors and retinal pigment epithelium directly, but it also requires specialized surgery and creates procedural burdens that are not trivial.
An in-office intravitreal procedure could make treatment logistically simpler if MOGENRY is approved under that administration model. Nanoscope has highlighted the one-time in-office nature of the therapy as one of its practical advantages.
Ease of delivery does not eliminate risk. Intravitreal gene therapy can still produce inflammation, immune reactions or other ocular complications, and viral vectors may behave differently depending on dose and patient immunity. The final label, risk-management requirements and administration protocol will therefore matter greatly.
What does “gene agnostic” really mean for patient testing?
Gene agnostic does not mean genetic testing suddenly becomes useless. Genetic diagnosis can still help confirm retinitis pigmentosa, identify syndromic conditions, provide family counseling and determine whether a patient qualifies for another mutation-specific therapy or clinical trial.
The difference is that MOGENRY’s mechanism does not require a specific mutation as the therapeutic target. A patient could theoretically be eligible because the retina has reached a particular functional state rather than because one named gene is defective.
This could simplify access for people whose disease-causing mutation is unknown, difficult to classify or not addressed by an existing gene-replacement therapy. It could also make the therapy relevant across a broader cross-section of the RP community than a single-gene intervention.
The FDA will still need to define exactly which patients have “severe vision loss” under the eventual indication and what retinal structural or functional criteria determine eligibility. Those details may ultimately be as important as the gene-agnostic label itself.
How important is the long-term REMAIN follow-up?
Durability is central to the value proposition of any one-time gene therapy. A strong one-year visual improvement that fades rapidly would be clinically different from an effect persisting for several years.
Nanoscope has cited REMAIN long-term follow-up as part of the BLA support package, suggesting the company is attempting to demonstrate that gains observed during RESTORE are not merely transient.
Longer follow-up is also necessary for safety. AAV-based therapies can produce persistent expression, which is advantageous when the treatment works but makes delayed complications particularly important to monitor. Regulators need reassurance that inflammation, retinal structural changes or other adverse effects do not emerge years after dosing.
Because severe RP progresses slowly but relentlessly, long-term untreated natural history also matters. If treated patients maintain or improve visual function while similar untreated patients would ordinarily decline, durability becomes part of the disease-modification argument.
Could MOGENRY become a platform beyond retinitis pigmentosa?
Potentially. The underlying optogenetic logic is not specific to one RP mutation because it depends on surviving inner retinal cells rather than repairing the original photoreceptor defect. That opens the possibility of applying a similar strategy to other retinal degenerations involving photoreceptor loss.
Nanoscope has already discussed broader development in retinal disease, including geographic atrophy-related programs, although each indication requires its own evidence. The degree of inner-retinal preservation, visual circuitry and disease biology differs across conditions.
A successful first approval could therefore validate more than one product. It could establish regulatory and clinical confidence in the idea of restoring light sensitivity downstream of failed photoreceptors.
Failure would also be instructive. It would suggest that simply creating light-sensitive inner retinal cells may not provide enough functional vision or that safety, variability or patient selection limits the approach.
What should patients and retina specialists watch during FDA review?
The first issue is whether the FDA convenes an advisory committee, which would provide a public forum for discussing efficacy, safety and the interpretation of optogenetic endpoints. The second is whether the agency requests additional analyses or manufacturing information during review.
Manufacturing will matter because AAV gene therapies are complex biological products. Consistency in vector potency, purity and expression profile is essential, particularly when one dose may determine a patient’s long-term outcome.
The third issue is the eventual label. A broad indication for severe RP regardless of mutation would be commercially and clinically significant, while a narrower label based on specific baseline visual criteria could limit the eligible population.
Finally, clinicians will want to understand what “improved visual acuity” means in daily life. A patient with profound visual loss may consider even modest improvement transformative if it enables better navigation or object recognition. Regulators must evaluate standardized endpoints, but real-world value will ultimately be judged by whether patients can do things they could not do before.
The FDA has not approved MOGENRY yet. What it has done is accept a complete enough application to begin formal review. That alone puts Nanoscope closer than most optogenetic retinal programs have ever come to turning the idea of mutation-independent vision restoration into a marketed therapy.
